TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
Brief Summary: This was a two-arm, open-label, randomized, Phase III study comparing dabrafenib (GSK2118436) and trametinib (GSK1120212) combination therapy with vemurafenib.


Options:
A: Arm Label: Ipilimumab and Placebo matching Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Other: Placebo matching Nivolumab | Arm Label: Nivolumab and Placebo matching Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Other: Placebo matching Ipilimumab | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Ipilimumab and Placebo matching Nivolumab | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab and Placebo matching Ipilimumab | Intervention Type: OTHER; Name: Placebo matching Ipilimumab; Assigned to Arm(s): Nivolumab and Placebo matching Ipilimumab | Intervention Type: OTHER; Name: Placebo matching Nivolumab; Assigned to Arm(s): Ipilimumab and Placebo matching Nivolumab
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody, Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody | Intervention Type: DRUG; Name: MDX-010 (anti-CTLA4) monoclonal antibody; Assigned to Arm(s): 2, 3 | Intervention Type: BIOLOGICAL; Name: MDX-1379 (gp100) Melanoma Peptide Vaccine; Assigned to Arm(s): 1, 2
C: Arm Label: Placebo + Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Vemurafenib | Arm Label: Cobimetinib + Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Vemurafenib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Cobimetinib + Vemurafenib, Placebo + Vemurafenib | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Cobimetinib + Vemurafenib
D: Arm Label: Dabrafenib plus Trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Arm Label: Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vemurafenib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib plus Trametinib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib plus Trametinib

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Yoga And Cardiovascular Health Trial
Brief Summary: The benefits of alternative therapeutic approaches, such as yoga, are poorly understood and this is particularly true of the beneficial effects on cardiovascular disease (CVD) risk. It is hoped that a better understanding of the value of this therapy will provide a sound scientific basis for including yoga in mainstream clinical practice. The investigators propose to study a group of 80 participants (40 Indian Asians and 40 Europeans) recruited from a cardiac rehabilitation programme in West London post-angioplasty as treatment for an acute coronary syndrome. Those who agree will undergo a series of baseline and follow-up measurements. 20 Indian Asians and 20 Europeans will be randomized to the yoga intervention plus their standard cardiac rehabilitation programme (usual care), and the remaining 20 Indian Asians and 20 Europeans will be randomized to usual care alone. Baseline and follow-up measurements will be performed on all participants. In order to determine the acute effects of yoga the group randomised to the yoga intervention will also undergo a series of acute tests before and after their first yoga session.


Options:
A: Intervention Type: OTHER; Name: Peer Support; Assigned to Arm(s): N/A
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Healing Circles; Type: EXPERIMENTAL; Interventions: Behavioral: Healing Circles | Intervention Type: BEHAVIORAL; Name: Healing Circles; Assigned to Arm(s): Healing Circles
C: Arm Label: Yoga 12 week programme; Type: ACTIVE_COMPARATOR; Interventions: Other: Yoga | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Yoga; Assigned to Arm(s): Yoga 12 week programme
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic Pill Bottle, Incentives, Social Influence | Intervention Type: BEHAVIORAL; Name: Electronic Pill Bottle, Incentives, Social Influence; Assigned to Arm(s): Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women With Early Stage Breast Cancer
Brief Summary: RATIONALE: Duloxetine hydrochloride may lessen muscle, bone, and joint pain caused by hormone therapy. It is not yet known whether duloxetine hydrochloride is more effective than a placebo in treating patients with muscle, bone, and joint pain caused by hormone therapy.

PURPOSE: This randomized phase III trial studies how well duloxetine hydrochloride works compared to a placebo in treating muscle, bone, and joint pain in patients with early-stage breast cancer receiving hormone therapy.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amitriptyline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Nortriptyline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nortriptyline Hydrochloride | Arm Label: Placebo (for nortriptyline); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for nortriptyline) | Intervention Type: DRUG; Name: Nortriptyline Hydrochloride; Assigned to Arm(s): Nortriptyline | Intervention Type: DRUG; Name: Placebo (for nortriptyline); Assigned to Arm(s): Placebo (for nortriptyline)
C: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
D: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women With Early Stage Breast Cancer
Brief Summary: RATIONALE: Duloxetine hydrochloride may lessen muscle, bone, and joint pain caused by hormone therapy. It is not yet known whether duloxetine hydrochloride is more effective than a placebo in treating patients with muscle, bone, and joint pain caused by hormone therapy.

PURPOSE: This randomized phase III trial studies how well duloxetine hydrochloride works compared to a placebo in treating muscle, bone, and joint pain in patients with early-stage breast cancer receiving hormone therapy.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Questioners | Arm Label: B; Type: EXPERIMENTAL; Interventions: Behavioral: STAR website | Intervention Type: BEHAVIORAL; Name: Questioners; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: STAR website; Assigned to Arm(s): B
B: Arm Label: Tamoxifen; Type: EXPERIMENTAL; Interventions: Drug: tamoxifen citrate | Arm Label: Letrozole; Type: EXPERIMENTAL; Interventions: Drug: letrozole | Arm Label: Tamoxifen, then letrozole; Type: EXPERIMENTAL; Interventions: Drug: letrozole, Drug: tamoxifen citrate | Arm Label: Letrozole, then tamoxifen; Type: EXPERIMENTAL; Interventions: Drug: letrozole, Drug: tamoxifen citrate | Intervention Type: DRUG; Name: letrozole; Assigned to Arm(s): Letrozole, Letrozole, then tamoxifen, Tamoxifen, then letrozole | Intervention Type: DRUG; Name: tamoxifen citrate; Assigned to Arm(s): Letrozole, then tamoxifen, Tamoxifen, Tamoxifen, then letrozole
C: Arm Label: vitamin D3; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): vitamin D3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
Brief Summary: The overall objective of this drug trial is to determine whether the treatment of acute hyperammonemia with N-carbamyl-L-glutamate (NCG, Carglumic acid) in propionic acidemia (PA), methylmalonic acidemia (MMA), late-onset CPS1 deficiency (CPSD) and late-onset Ornithine transcarbamylase deficiency (OTCD) accelerates the resolution of hyperammonemia efficiently and safely.

The primary goal is to determine if the study drug (NCG) efficiently reduces ammonia levels following a hyperammonemia episode(s).

Secondly, the investigators want to know if treatment with this study drug (NCG) efficiently improves neurologic function, reduces plasma glutamine levels and lessens the duration of hospitalization after each episode of hyperammonemia.


Options:
A: Arm Label: Standard infant formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard infant formula | Arm Label: Protein-reduced whey formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein-reduced whey formula | Arm Label: Protein-reduced α-lactalbumin formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein-reduced α-lactalbumin formula | Arm Label: Breast-feeding; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein-reduced α-lactalbumin formula; Assigned to Arm(s): Protein-reduced α-lactalbumin formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein-reduced whey formula; Assigned to Arm(s): Protein-reduced whey formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard infant formula; Assigned to Arm(s): Standard infant formula
B: Arm Label: Isoleucine; Type: ACTIVE_COMPARATOR; Interventions: Other: ORS + Isoleucine | Arm Label: ORS without Isoleucine; Type: PLACEBO_COMPARATOR; Interventions: Other: ORS without Isoleucine | Intervention Type: OTHER; Name: ORS + Isoleucine; Assigned to Arm(s): Isoleucine | Intervention Type: OTHER; Name: ORS without Isoleucine; Assigned to Arm(s): ORS without Isoleucine
C: Arm Label: Trophamine; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Primene 10% from Baxter; Type: EXPERIMENTAL; Interventions: Other: Primene 10 % from Baxter | Intervention Type: OTHER; Name: Primene 10 % from Baxter; Assigned to Arm(s): Primene 10% from Baxter
D: Arm Label: Active Comparator; Type: EXPERIMENTAL; Interventions: Drug: Carbaglu | Arm Label: Placebo Comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Carbaglu; Assigned to Arm(s): Active Comparator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Dose Ranging Safety and Efficacy Study of FG 4592 in Non-dialysis Chronic Kidney Disease (CKD) Subjects With Anemia
Brief Summary: The primary purpose of this study is to evaluate efficacy and safety of FG-4592 in the correction of anemia in non-dialysis chronic kidney disease patients.


Options:
A: Arm Label: FG-4592; Type: EXPERIMENTAL; Interventions: Drug: FG-4592 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FG-4592; Assigned to Arm(s): FG-4592 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Daprodustat; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat, Drug: Placebo, Drug: Iron Therapy | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa, Drug: Placebo, Drug: Iron Therapy | Intervention Type: DRUG; Name: Daprodustat; Assigned to Arm(s): Daprodustat | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Daprodustat, Darbepoetin alfa | Intervention Type: DRUG; Name: Iron Therapy; Assigned to Arm(s): Daprodustat, Darbepoetin alfa
C: Arm Label: 0.5mg GSK1278863; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: 2mg GSK1278863; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: 5mg GSK1278863; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Other: Placebo | Intervention Type: DRUG; Name: GSK1278863; Assigned to Arm(s): 0.5mg GSK1278863, 2mg GSK1278863, 5mg GSK1278863 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: ASP1517 Low dose group; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: ASP1517 Middle dose group; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: ASP1517 High dose group; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: Darbepoetin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Intervention Type: DRUG; Name: roxadustat; Assigned to Arm(s): ASP1517 High dose group, ASP1517 Low dose group, ASP1517 Middle dose group | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Darbepoetin group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-month, Phase IIIb, Open-label, Randomized, Active Controlled, 3-arm, Multicenter Study Assessing the Efficacy and Safety of an Individualized, Stabilization-criteria-driven PRN Dosing Regimen With 0.5-mg Ranibizumab Intravitreal Injections Applied as Monotherapy or With Adjunctive Laser Photocoagulation in Comparison to Laser Photocoagulation in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
Brief Summary: This study will generate comparative data for 0.5-mg ranibizumab using PRN dosing administered with or without adjunctive laser treatment versus laser photocoagulation (the current standard of care) up to Month 6 in patients with visual impairment due to ME secondary to BRVO. Additionally the results of this study will provide long-term (24-month) safety and efficacy data for ranibizumab, administered with or without adjunctive laser treatment in this indication.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser photocoagulation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser photocoagulation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): 2, 3 | Intervention Type: PROCEDURE; Name: Laser photocoagulation; Assigned to Arm(s): 1, 2
B: Arm Label: Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravitreal injection of bevacizumab | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravitreal injection of ranibizumab (0.5 mg per dose) | Intervention Type: DRUG; Name: Intravitreal injection of bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: Intravitreal injection of ranibizumab (0.5 mg per dose); Assigned to Arm(s): Ranibizumab
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Arm Label: 1-ranibizumab monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: 2-ranibizumab with laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: 3-laser monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): 1-ranibizumab monotherapy, 2-ranibizumab with laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): 2-ranibizumab with laser, 3-laser monotherapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Spaulding-Harvard Spinal Cord Injury (SH-SCI) Study: Effects of tDCS on Chronic Pain in Spinal Cord Injury.
Brief Summary: The purpose of this study is to see the effects of transcranial direct current stimulation (tDCS) on the pain associated with spinal cord injury. This study is part of the Spaulding-Harvard Model System. The investigators hypothesize that there will be a decrease in pain levels with active stimulation, when compared to sham stimulation, using a 3 week stimulation schedule- 1 week of stimulation (5 consecutive days) followed by 2 weeks of stimulation (10 consecutive days) after a 3-month follow up visit. The subject will also have follow ups at 2, 4 and 8 weeks after the second course of stimulation.

If a subject receives sham during the experiment, he/she may enroll in an open-label portion of the study and receive 10 days of active stimulation.


Options:
A: Arm Label: Active TMS; Type: ACTIVE_COMPARATOR; Interventions: Device: Active TMS | Arm Label: Sham TMS; Type: SHAM_COMPARATOR; Interventions: Device: Sham TMS | Intervention Type: DEVICE; Name: Active TMS; Assigned to Arm(s): Active TMS | Intervention Type: DEVICE; Name: Sham TMS; Assigned to Arm(s): Sham TMS
B: Arm Label: Group I; Type: ACTIVE_COMPARATOR; Interventions: Device: Real tDCS | Arm Label: Group II; Type: SHAM_COMPARATOR; Interventions: Device: Sham tDCS | Intervention Type: DEVICE; Name: Real tDCS; Assigned to Arm(s): Group I | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Group II
C: Arm Label: Both Sham rTMS and Neuroacupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Sham rTMS, Device: Sham Neuroacupuncture | Arm Label: Active rTMS and sham Neuroacupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Active rTMS, Device: Sham Neuroacupuncture | Arm Label: Sham rTMS and Active Neuroacupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Sham rTMS, Device: Active Neuroacupuncture | Arm Label: Both Active rTMS and Neuroacupuncture; Type: ACTIVE_COMPARATOR; Interventions: Device: Active rTMS, Device: Active Neuroacupuncture | Intervention Type: DEVICE; Name: Active rTMS; Assigned to Arm(s): Active rTMS and sham Neuroacupuncture, Both Active rTMS and Neuroacupuncture | Intervention Type: DEVICE; Name: Sham rTMS; Assigned to Arm(s): Both Sham rTMS and Neuroacupuncture, Sham rTMS and Active Neuroacupuncture | Intervention Type: DEVICE; Name: Active Neuroacupuncture; Assigned to Arm(s): Both Active rTMS and Neuroacupuncture, Sham rTMS and Active Neuroacupuncture | Intervention Type: DEVICE; Name: Sham Neuroacupuncture; Assigned to Arm(s): Active rTMS and sham Neuroacupuncture, Both Sham rTMS and Neuroacupuncture
D: Arm Label: Active tDCS; Type: EXPERIMENTAL; Interventions: Device: Transcranial direct current stimulation (tDCS) | Arm Label: Sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: Transcranial direct current stimulation (tDCS) | Intervention Type: DEVICE; Name: Transcranial direct current stimulation (tDCS); Assigned to Arm(s): Active tDCS, Sham tDCS

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BAX 855 (PEGylated Recombinant Factor VIII): A Phase 1, Prospective, Open Label, Cross-Over, Dose-Escalation Study in Previously Treated Patients (PTPs) With Severe (FVIII < 1%) Hemophilia A
Brief Summary: The objectives of this study are to assess the tolerability and safety after single dose treatments of BAX 855 in previously treated patients (PTPs) with severe hemophilia A, to determine the pharmacokinetic (PK) parameters of BAX 855 compared in crossover with ADVATE, and to evaluate the impact of anti-polyethylene glycol (PEG) antibodies on PK parameters.


Options:
A: Arm Label: Group 1; Type: OTHER; Interventions: Genetic: Gene Transfer, Drug: scAAV2/8-LP1-hFIXco | Intervention Type: GENETIC; Name: Gene Transfer; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: scAAV2/8-LP1-hFIXco; Assigned to Arm(s): Group 1
B: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, Biological: PEGylated Recombinant Factor VIII | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, Biological: PEGylated Recombinant Factor VIII | Intervention Type: BIOLOGICAL; Name: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method; Assigned to Arm(s): Cohort 1, Cohort 2 | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Cohort 1, Cohort 2
C: Arm Label: Fixed Weekly Interval; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc), Drug: rFIX | Arm Label: Individualized Interval; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc) | Arm Label: On Demand; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc) | Arm Label: Surgery; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc) | Intervention Type: DRUG; Name: Factor IX (rFIXFc); Assigned to Arm(s): Fixed Weekly Interval, Individualized Interval, On Demand, Surgery | Intervention Type: DRUG; Name: rFIX; Assigned to Arm(s): Fixed Weekly Interval
D: Arm Label: SPK-9001; Type: EXPERIMENTAL; Interventions: Biological: SPK-9001 | Intervention Type: BIOLOGICAL; Name: SPK-9001; Assigned to Arm(s): SPK-9001

Answer: B